Yes, most people can have Dysport and Restylane at the same appointment, and the two are routinely combined - but no published trial has tested the order or the spacing. Dysport is a botulinum toxin that relaxes a muscle. Restylane is a family of hyaluronic acid gel fillers that add volume. They are not competing options.
Their approved territories barely touch. Dysport's only US cosmetic indication is moderate to severe glabellar lines - the frown lines between the brows - in adults under 65, at a label dose of 50 Units given as five equal 10-Unit injections. Those are Dysport Units and they convert to no other brand. The Restylane family's approvals are spread across the rest of the face, area by area and product by product.
What is actually published about combining them is thin but real. Randomized trials have tested adding a hyaluronic acid filler to a botulinum toxin treatment, and found the combination did better than either alone in the lower face and lasted longer in the forehead and glabella. None of those trials used Dysport or Restylane by name, and none of them compared one order against the other, or one appointment against two.
Its FDA label calls it "an acetylcholine release inhibitor and a neuromuscular blocking agent."
Class III devices approved through the FDA's premarket approval route, one named area at a time.
No US cosmetic indication for crow's feet or forehead lines.
Restylane and Restylane-L: facial wrinkles and folds, and lips. Lyft with Lidocaine: facial folds, cheeks, the backs of the hands (2018) and the chin (2025). Silk: lips and perioral lines. Refyne and Defyne: facial wrinkles and folds, with Defyne also approved for the chin (2021). Kysse: lips and upper perioral lines. Contour: cheeks, and temple hollowing (2026). Eyelight: under-eye hollowing (2023).
In the Restylane Lyft cheek trial, roughly half of treated subjects had at least one adverse event, most commonly injection-site haematoma (18.1%), pain (8.5%) and swelling (7.5%), with a median duration of 11 days or less.
The label states these units cannot be converted into any other brand's units.
Restylane syringes come in 0.5 mL and 1.0 mL fills depending on the product; Restylane Eyelight is supplied in 0.5 mL.
In the US that use is off-label - the FDA labeling for Hylenex lists three indications and dissolving filler is not one. In laboratory testing, Restylane products degraded at lower enzyme doses than Juvederm gels did.
It occupies no space. It cannot fill a hollow cheek, a flat chin or a thin lip.
A crease produced purely by muscle contraction is not a volume problem, and adding gel to it treats the wrong mechanism.
Usually, yes, and it is common practice. What does not exist is a trial that compared same-day treatment against separate appointments, so nobody can tell you that one is safer or works better. Anyone who does tell you that is stating a preference, not a finding.
There are two practical points worth raising with your injector before you book both.
Filler swells and bruises, and that makes the result hard to judge for several days: If you are having both to a deadline, the filler is the part that determines when your face looks settled.
If a problem appears after a combined appointment, it is not always obvious which product caused it: That matters more for the delayed problems - a lump, or new swelling weeks later - than for the immediate ones.
No published evidence establishes an order: Any sequence you are given is a clinic's own routine.
What is worth asking about instead is the plan itself: which specific Restylane product is going where, how much, and what it is approved for. Restylane Contour holds a cheek indication and, since 2026, a temple indication; Restylane Defyne holds a chin indication; Restylane Eyelight holds an under-eye indication and requires the injector to have completed a specific training programme. Those details change the answer more than the running order of the appointment does.
These signs can mean filler has entered a blood vessel. Time matters in hours.
Sudden vision change, blurring or loss of vision in either eye
Pain that is severe or out of proportion to the procedure
Skin that turns white or pale soon after the injection, then goes dusky, grey, purple or mottled
Any stroke-like symptom: weakness, drooping, slurred speech, confusion
Filler-related vision loss is usually permanent: In a review of 511 published cases, of the 318 that reported a visual outcome, 6.0% recovered completely and 68.2% did not recover at all. Do not use pain as your gate - it was mild or absent in 47% of intravascular events reported in a survey of experienced injectors.
Swelling that keeps growing after the first few days
A lump that will not settle
Redness spreading outward from the site, or a fever
Tenderness or firmness appearing weeks or months later
Filler that appears to have moved
A drooping eyelid or brow after the toxin